Get startedLog in
    Picture of Tenaya Therapeutics logo

    TNYA — Tenaya Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapSucker Stock
    All News

    Tenaya Therapeutics Q1 net loss widens, misses analyst expectations

    Picture of Tenaya Therapeutics logoTenaya Therapeutics
    06/05/2026 21:35
    Overview

US biotech for heart disease posted Q1 net loss and operating loss, both missing analyst expectations

Operating expenses for Q1 fell yr/yr due to lower R&D and G&A costs

Company entered research collaboration with Alnylam, receiving $10 mln upfront payment

Outlook

Tenaya expects interim MyPEAK-1 data for TN-201 in Q2 2026

Company plans to present one-year RIDGE-1 TN-401 data at ASGCT in May 2026

Tenaya expects cash resources to fund operations into second half of 2027

Result Drivers

LOWER OPERATING EXPENSES - Co said Q1 operating expenses declined yr/yr due to reduced R&D and G&A costs

CLINICAL PROGRAM ADVANCEMENT - Co highlighted ongoing progress in TN-201 and TN-401 gene therapy trials, including protocol optimizations to reduce immunosuppression burden

ALNYLAM COLLABORATION - Co received $10 mln upfront payment from new research collaboration with Alnylam

Company press release: ID:nGNX2kfkY2

Key Details


    MetricBeat/MissActualConsensus Estimate
    Q1 Net IncomeMiss-$19.27 mln-$10.90 mln (3 Analysts)
    Q1 Operating IncomeMiss-$20.07 mln-$11.81 mln (3 Analysts)
    Q1 Pretax ProfitMiss-$19.27 mln-$10.90 mln (3 Analysts)
    Q1 Basic EPS-$0.09
    Q1 Operating Expenses$20.29 mln
    

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Tenaya Therapeutics Inc is $4.00, about 430.3% above its May 5 closing price of $0.75

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

    Recent news on Tenaya Therapeutics

    See all news